Skip to main content
Clinical Trials/KCT0007987
KCT0007987
Not yet recruiting
未知

Multicenter clinical evaluation study of clinical effectivity of AptoDetectTM-Lung for Auxiliary diagnostics of Non-Small Cell Lung Cancer [Apto_RADS]

Kyung Hee University Hospital0 sites2,994 target enrollmentTBD

Overview

Phase
未知
Intervention
Not specified
Conditions
Symptoms, signs and abnormal clinical and laboratory findings, NEC
Sponsor
Kyung Hee University Hospital
Enrollment
2994
Status
Not yet recruiting
Last Updated
3 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
3 years ago
Study Type
Interventional Study
Sex
All

Investigators

Sponsor
Kyung Hee University Hospital

Eligibility Criteria

Inclusion Criteria

  • 1\) A patient who has given written consent to participate in this study
  • 2\) Adult men and women over 19 years of age
  • 3\) Patients with solid nodules or part solid nodules corresponding to categories 3 to 4 according to the Lung\-RADS® version 1\.1 pulmonary nodule categorization guidelines
  • However, patients in category S according to the Lung\-RADS® version 1\.1 pulmonary nodule categorization guidelines can also be enrolled.

Exclusion Criteria

  • 1\) Patients with ground glass nodules (GGO) in the Lung\-RADS® version 1\.1 pulmonary nodule categorization guidelines
  • 2\) Any pulmonary infection requiring current treatment (both oral or intravenous)
  • However, if the researcher determines that treatment for lung infection has been completed, enrollment is possible.
  • 3\) Patients with histologically confirmed malignant tumors prior to participation in this study
  • However, registration is possible in the following cases, but registration is not possible if the patient is accompanied by a malignant tumor requiring current treatment.
  • ? Cases confirmed as malignant tumors (including lung cancer) but in remission for more than 5 years after completion of treatment
  • ? Effectively treated non\-melanoma skin cancer, cervical carcinoma in situ, mammary ductal carcinoma in situ, localized prostate cancer treated for curative purposes, and thyroid cancer can be registered.
  • 4\) Pregnant women

Outcomes

Primary Outcomes

Not specified

Similar Trials